<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410121</url>
  </required_header>
  <id_info>
    <org_study_id>2016-4-46-002</org_study_id>
    <nct_id>NCT03410121</nct_id>
  </id_info>
  <brief_title>Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy</brief_title>
  <acronym>PACPAC-EPOC</acronym>
  <official_title>Phase IV Study Comparing Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Intravenous Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the humeral and thoracic implantation of a central venous
      access by an implantable device in patients with solids tumors who require intravenous
      chemotherapy. This is a monocentric randomized study. 572 patients will be recruited for 2
      years. They will be randomized either in the thoracic implantation, either in the humeral
      implantation Due to the 1:3 randomization, 143 patients will be randomized in the humeral arm
      and 429 into the thoracic one. Number of complications related to the implantable device,
      medico-economic analysis as well as patient satisfaction will be assessed.

      Every patients with solid tumor requiring medical device implantation for intravenous
      chemotherapy treatment will be eligible.

      Both humeral and thoracic implantation of medical device are standard procedures. The
      randomization in a specific arm is the study procedure and is considered as an interventional
      study in France.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of complications related to Implantable Venous Access Device</measure>
    <time_frame>3 months after medical device placement</time_frame>
    <description>Number of complications that will be recorded by medical oncologist</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">572</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Chemotherapy Treatment</condition>
  <condition>Advanced or Metastasis Stage</condition>
  <arm_group>
    <arm_group_label>Standard 1 : Thoracic location</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard 2 : Humeral location</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.</intervention_name>
    <description>Implantation of intravenous medical device in thoracic location</description>
    <arm_group_label>Standard 1 : Thoracic location</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vital Port®Minititanium</intervention_name>
    <description>Implantation of intravenous medical device in humeral location</description>
    <arm_group_label>Standard 2 : Humeral location</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with solid tumors at an Advanced or metastasis stage requiring placement of
             implantable catheter for intravenous chemotherapy treatment

          -  Older than 18 years

          -  Express signed consent

        Exclusion Criteria:

          -  Life expectancy less than 12 months assessed by investigator

          -  Infection or uncontrolled suspected infection

          -  Medical contraindication to port implantation by catheter in thoracic or humeral
             location

          -  Pregnant or lactating women

          -  Abnormal coagulation

          -  Immunosuppressed patients (for example known hepatitis B or C, or known positive Human
             Immunodeficiency Virus due to the spreading risk)

          -  Patient not affiliated to the French social security

          -  Access time to the humeral or thoracic port placement higher than 15 days (from the
             randomization theoretical date)

          -  Protected Adult or adult deprived of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence CROUZET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis, Rennes, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence CROUZET, MD</last_name>
    <phone>+ 33 2 99 25 30 00</phone>
    <email>l.crouzet@rennes.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence CROUZET, MD</last_name>
    <phone>+ 33 2 99 25 30 00</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <state>Brittany</state>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence CROUZET, MD</last_name>
      <phone>+33 299 25 30 00</phone>
      <email>l.crouzet@rennes.fnclcc.fr</email>
    </contact>
    <contact_backup>
      <last_name>Martine GESTIN, PhD</last_name>
      <phone>+33 299 25 30 36</phone>
      <email>m.gestin@rennes.fnclcc.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

